Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2020 | Ruxolitinib for treatment of CRS in R/R AML treated with flotetuzumab

John DiPersio • 8 Dec 2020

ASH 2020

Acute Myeloid Leukemia Leukemia Antibodies CAR-T Flotetuzumab Ruxolitinib

John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, outlines the results of a study investigating prophylactic ruxolitinib for the treatment of cytokine release syndrome (CRS) in relapsed/refractory (R/R) acute myeloid leukemia (AML) patients treated with flotetuzumab. The study found that prophylactic ruxolitinib produced a clear difference in cytokine profiles but no discernible improvement in clinical CRS or response rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates

John DiPersio • 21 Feb 2023

LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

John DiPersio • 21 Feb 2023

ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL

John DiPersio • 21 Feb 2023

Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients

John DiPersio • 21 Feb 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024